GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (XTAE:KMDA) » Definitions » Revenue per Share

Kamada (XTAE:KMDA) Revenue per Share : ₪10.32 (TTM As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Kamada Revenue per Share?

Kamada's revenue per share for the three months ended in Mar. 2024 was ₪2.35. Kamada's revenue per share for the trailing twelve months (TTM) ended in Mar. 2024 was ₪10.32.

Warning Sign:

Kamada Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue Per Share Growth Rate of Kamada was -1.00% per year. During the past 3 years, the average Revenue Per Share Growth Rate was -3.90% per year. During the past 5 years, the average Revenue Per Share Growth Rate was -2.30% per year. During the past 10 years, the average Revenue Per Share Growth Rate was 3.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Kamada's Revenue per Share or its related term are showing as below:

XTAE:KMDA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.7   Med: 4   Max: 61.8
Current: -3.9

During the past 13 years, Kamada's highest 3-Year average Revenue Per Share Growth Rate was 61.80% per year. The lowest was -8.70% per year. And the median was 4.00% per year.

XTAE:KMDA's 3-Year Revenue Growth Rate is ranked worse than
77.01% of 922 companies
in the Drug Manufacturers industry
Industry Median: 6.45 vs XTAE:KMDA: -3.90

Kamada Revenue per Share Historical Data

The historical data trend for Kamada's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Revenue per Share Chart

Kamada Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.51 10.98 8.48 10.59 9.76

Kamada Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.50 3.04 2.59 2.35 2.35

Competitive Comparison of Kamada's Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kamada's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kamada's PS Ratio distribution charts can be found below:

* The bar in red indicates where Kamada's PS Ratio falls into.



Kamada Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Kamada's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=523.594/53.676
=9.75

Kamada's Revenue Per Share for the quarter that ended in Mar. 2024 is calculated as

Revenue Per Share (Q: Mar. 2024 )=Revenue (Q: Mar. 2024 )/Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
=138.636/59.125
=2.34

Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪10.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kamada  (XTAE:KMDA) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Kamada Revenue per Share Related Terms

Thank you for viewing the detailed overview of Kamada's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Kamada (XTAE:KMDA) Business Description

Traded in Other Exchanges
Address
2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Kamada (XTAE:KMDA) Headlines

From GuruFocus

Kamada Announces Planned Transition of Chief Financial Officer

By Value_Insider Value_Insider 12-19-2022

Kamada to Present at the Credit Suisse 31st Annual Healthcare Conference

By Value_Insider Value_Insider 10-26-2022